Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $30.00 at Evercore ISI

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price target boosted by Evercore ISI from $25.00 to $30.00 in a report issued on Wednesday morning, Benzinga reports. Evercore ISI currently has an outperform rating on the stock.

Other research analysts have also recently issued reports about the stock. Wedbush reissued an outperform rating and set a $30.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday. TheStreet raised shares of Kiniksa Pharmaceuticals from a d+ rating to a c rating in a research note on Thursday, February 29th.

Kiniksa Pharmaceuticals Trading Up 1.0 %

KNSA stock opened at $17.86 on Wednesday. The firm has a 50 day moving average of $19.36 and a 200-day moving average of $18.00. Kiniksa Pharmaceuticals has a 12-month low of $10.65 and a 12-month high of $22.09. The company has a market cap of $1.26 billion, a price-to-earnings ratio of 162.38 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, April 23rd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11). Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.32%. The company had revenue of $79.90 million for the quarter, compared to analyst estimates of $76.97 million. During the same quarter in the previous year, the business posted ($0.18) earnings per share. Kiniksa Pharmaceuticals’s revenue was up 65.4% on a year-over-year basis. Sell-side analysts forecast that Kiniksa Pharmaceuticals will post -0.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 5,582 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total value of $117,222.00. Following the completion of the sale, the chief executive officer now directly owns 65,012 shares of the company’s stock, valued at approximately $1,365,252. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,659 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $21.45, for a total value of $207,185.55. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at approximately $377,262.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sanj K. Patel sold 5,582 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total transaction of $117,222.00. Following the sale, the chief executive officer now directly owns 65,012 shares of the company’s stock, valued at $1,365,252. The disclosure for this sale can be found here. In the last three months, insiders sold 33,109 shares of company stock valued at $709,929. Company insiders own 54.23% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in KNSA. IFP Advisors Inc acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth $65,000. Linden Thomas Advisory Services LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 100.0% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 115,891 shares of the company’s stock worth $2,013,000 after buying an additional 57,942 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Kiniksa Pharmaceuticals by 13.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 146,568 shares of the company’s stock worth $2,546,000 after buying an additional 17,790 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Kiniksa Pharmaceuticals by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 55,047 shares of the company’s stock worth $956,000 after buying an additional 26,002 shares during the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth $777,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.